{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019314","form_type":"8-K","ticker":null,"cik":"0001106838","company_name":"Sonnet BioTherapeutics Holdings, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.305720+00:00","generated_at":"2026-06-02T00:16:06.366306+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sonnet Q2 cash $3.8M; runway into July/August 2024; pipeline shifts to DPN","bullets":["Cash $3.8M as of Mar 31, 2024; no debt; expects runway into July 2024, potentially August with cost cuts.","Q2 R&D expenses $2.2M (down from $3.8M), G&A $1.7M (down from $1.9M) from cost-saving initiatives.","Received $4.3M net proceeds from NJ NOL sale; entered equity facility with Chardan for capital raise.","SON-1010 Phase 1 data published showing safety up to 300 ng/kg; SON-080 cleared by DSMB.","CIPN program placed on hold; targeting diabetic peripheral neuropathy; seeking partnerships for SON-080."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019314","json":"https://secwatch.observer/filing/0001493152-24-019314.json","markdown":"https://secwatch.observer/filing/0001493152-24-019314.md","text":"https://secwatch.observer/filing/0001493152-24-019314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1106838/000149315224019314/0001493152-24-019314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1106838/000149315224019314/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:16:06.366306+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6c2a459837c2e36895b242fda780f7fb580092ff","claim":"Sonnet BioTherapeutics Holdings, Inc. reported financial results for three months ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, Sonnet BioTherapeutics Holdings, Inc. (the “Registrant”) issued a press release regarding its financial results for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1106838/000149315224019314/0001493152-24-019314-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6e0fc0d394d96cd20da32b1fd66e2680e3ec4b48","claim":"Sonnet BioTherapeutics Holdings, Inc. reported financial results for three months and six months ended March 31, 2024.","evidence_excerpt":"Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months and six months ended March 31, 2024 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1106838/000149315224019314/0001493152-24-019314-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months and six months ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}